BIOMAT Database Logo BIOMAT Database Logo

Childhood vaccination against chickenpox: an analysis of benefits and costs. 1994

D M Huse, and H C Meissner, and M J Lacey, and G Oster
Policy Analysis Inc., Brookline Massachusetts 02146.

OBJECTIVE To estimate the economic costs and benefits of routine childhood vaccination against varicella infection. METHODS Decision-analytic model of the incidence and costs of chickenpox in children assumed to receive varicella vaccine at age 15 months in conjunction with the measles-mumps-rubella vaccine, or not to be vaccinated against varicella. METHODS Hypothetical cohort of 100,000 children. METHODS Costs of vaccination, cumulative incidence of chickenpox to age 25 years, and related disease costs, including medical treatment and work loss. RESULTS Vaccination of 100,000 children against varicella at age 15 months would cost $4,812,000. The expected number of cases of chickenpox to age 25 years would be reduced from 95,400 to 4800; costs of medical treatment and work loss would correspondingly decline by $1,678,000 and $9,781,000, respectively. On balance, vaccination is estimated to yield net economic benefits of $6,647,000, or $66.47 per vaccinee. CONCLUSIONS Vaccination against varicella infection is cost-effective and should be part of the routine immunization schedule for U.S. children.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008962 Models, Theoretical Theoretical representations that simulate the behavior or activity of systems, processes, or phenomena. They include the use of mathematical equations, computers, and other electronic equipment. Experimental Model,Experimental Models,Mathematical Model,Model, Experimental,Models (Theoretical),Models, Experimental,Models, Theoretic,Theoretical Study,Mathematical Models,Model (Theoretical),Model, Mathematical,Model, Theoretical,Models, Mathematical,Studies, Theoretical,Study, Theoretical,Theoretical Model,Theoretical Models,Theoretical Studies
D002644 Chickenpox A highly contagious infectious disease caused by the varicella-zoster virus (HERPESVIRUS 3, HUMAN). It usually affects children, is spread by direct contact or respiratory route via droplet nuclei, and is characterized by the appearance on the skin and mucous membranes of successive crops of typical pruritic vesicular lesions that are easily broken and become scabbed. Chickenpox is relatively benign in children, but may be complicated by pneumonia and encephalitis in adults. (From Dorland, 27th ed) Varicella,Chicken Pox
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.

Related Publications

D M Huse, and H C Meissner, and M J Lacey, and G Oster
Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs.
July 2000, The American journal of managed care,
D M Huse, and H C Meissner, and M J Lacey, and G Oster
[Systematic vaccination against chickenpox: benefits and controversies].
January 1996, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
D M Huse, and H C Meissner, and M J Lacey, and G Oster
[Analysis on costs-benefits of vaccination against measles (author's transl)].
June 1979, Annali Sclavo; rivista di microbiologia e di immunologia,
D M Huse, and H C Meissner, and M J Lacey, and G Oster
Routine vaccination against chickenpox?
April 2012, Drug and therapeutics bulletin,
D M Huse, and H C Meissner, and M J Lacey, and G Oster
[Analysis of the benefits and costs of vaccination].
November 1983, Casopis lekaru ceskych,
D M Huse, and H C Meissner, and M J Lacey, and G Oster
Cost-benefit analysis of routine childhood vaccination against chickenpox in Taiwan: decision from different perspectives.
September 2003, Vaccine,
D M Huse, and H C Meissner, and M J Lacey, and G Oster
[Costs and benefits of vaccination against Haemophilus influenzae type b].
January 1991, Nederlands tijdschrift voor geneeskunde,
D M Huse, and H C Meissner, and M J Lacey, and G Oster
Benefits and costs of vaccination.
January 1992, Vaccine,
D M Huse, and H C Meissner, and M J Lacey, and G Oster
[Protective effect of vaccination against chickenpox].
November 2000, Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne,
D M Huse, and H C Meissner, and M J Lacey, and G Oster
[Vaccination against chickenpox, shingles and rotavirus-infection].
January 2009, Nederlands tijdschrift voor geneeskunde,
Copied contents to your clipboard!